Drug Information

Drug (ID: DG01121) and It's Reported Resistant Information

• Name: Oxycodone
• Synonyms: Oxycodone; Dihydrone; Dihydrohydroxycodeinone; Oxycodeinone; Dihydroxycodeinone; Oxicon; Diphydrone; Eucodalum; Oxycodon; Percobarb; Roxicodone; Oxycontin; 76-42-6; Dihydro-14-hydroxycodeinone; (-)-14-Hydroxydihydrocodeinone; Oxicodona; Oxycodonum; Oxycodonum [INN-Latin]; Oxicodona [INN-Spanish]; Percodan; Xtampza; Codeinone, dihydrohydroxy-; Codeinone, dihydro-14-hydroxy-; PTI-821; 4,5alpha-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one; UNII-CD35PMG570; Oxicone; 4,5-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one; 14-Hydroxydihydrocodeinone; Oxanest; Endone; CD35PMG570; CHEBI:7852; Oxyfast; Supendol; PF-00345439; OxyIR; Eubine [France]; NSC-19043; Tekodin (free base); Supendol [Canada]; Endine (Australia); Ossicodone [DCIT]; Ossicodone; NSC 19043; Codeinone, 7,8-dihydro-14-hydroxy-; Oxycodone Concentrate; Oxycodone [USAN:INN:BAN]; Dihydrohydroxycondeinone; Avridi; Oxyneo; Pancodone Retard; Pancodone retard (United Kingdom); Xtampza ER; Apo-oxycodone CR; (4R,4aS,7aR,12bS)-4a-hydroxy-9-methoxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one; (4R,4aS,7aR,12bS)-4a-hydroxy-9-methoxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one; (-)-Oxycodone; CHEMBL656; HSDB 3142; Oxycodone (USAN/INN); EINECS 200-960-2; oxymorphone 3-methyl ether; BRN 0043446; Pavinal; 4,5.alpha.-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one; Oxycodone cii; N02AA05; Morphinan-6-one, 4,5-epoxy-14-hydroxy-3-methoxy-17-methyl-, (5alpha)-; Morphinan-6-one, 4,5alpha-epoxy-14-hydroxy-3-methoxy-17-methyl-; SCHEMBL2737; Pti 821; GTPL7093; IDS-NO-002; PF06; DTXSID5023407; Codeinone,8-dihydro-14-hydroxy-; Oxycodone 0.1 mg/ml in Methanol; Oxycodone 1.0 mg/ml in Methanol; ZINC403533; 14-hydroxy-3-methoxy-17-methyl-4,5alpha-epoxymorphinan-6-one; NSC19043; BDBM50370595; Morphinan-6-one, 4,5-alpha-epoxy-14-hydroxy-3-methoxy-17-methyl-; (5alpha)-14-hydroxy-17-methyl-3-(methyloxy)-4,5-epoxymorphinan-6-one; DB00497; AC-16043; C08018; D05312; Q407535; Morphinan-6-one,5.alpha.-epoxy-14-hydroxy-3-methoxy-17-methyl-; Morphinan-6-one, 4,5alpha-epoxy-14-hydroxy-3-methoxy-17-methyl- (8CI); Morphinan-6-one,5-epoxy-14-hydroxy-3-methoxy-17-methyl-, (5.alpha.)-; WLN: T B6566 B6/CO 4ABBC R BX FV HO PN GHT&&TTJ CQ JO1 P1; 4aH-8,5-bcd]furan-5(6H)-one, 7,7a,8,9-tetrahydro-7a-hydroxy-3-methoxy-12-methyl-; Oxycodone solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; (1S,5R,13R,17S)-17-hydroxy-10-methoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10-trien-14-one
• Indication:
  In total 3 Indication(s)
  Back pain [ICD-11: ME84]; Approved; [1]
  Pain [ICD-11: MG30]; Approved; [1]
  Pain [ICD-11: MG30]; Approved; [1]
• Drug Resistance Disease(s):
  Disease(s) with Clinically Reported Resistance for This Drug (1 diseases)
  Osteosarcoma [ICD-11: 2B51]; [1]
• Target: Opioid receptor delta (OPRD1); OPRD_HUMAN; [1]
• Target: Opioid receptor mu (MOP); OPRM_HUMAN; [1]
• Formula: C18H21NO4
• IsoSMILES: CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O
• InChI: 1S/C18H21NO4/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10/h3-4,13,16,21H,5-9H2,1-2H3/t13-,16+,17+,18-/m1/s1
• InChIKey: BRUQQQPBMZOVGD-XFKAJCMBSA-N
• PubChem CID: 5284603
• ChEBI ID: CHEBI:7852
• TTD Drug ID: D03SKD
• VARIDT ID: DR00392
• DrugBank ID: DB00497

Type(s) of Resistant Mechanism of This Drug

  DISM: Drug Inactivation by Structure Modification

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Osteosarcoma [ICD-11: 2B51]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Drug Inactivation by Structure Modification (DISM)

Key Molecule: Cytochrome P450 family 3 subfamily A (CYP3A) [1]

• Molecule Alteration: Expression; Up-regulation
• Resistant Disease: Osteosarcoma [ICD-11: 2B51.0]
• Experimental Note: Identified from the Human Clinical Data
• Mechanism Description: Oxycodone is a semisynthetic opioid receptor agonist, and is frequently used for pain control in patients with cancer. Most oxycodone is metabolized by N-demethylation to noroxycodone by CYP3A. Rifampin is a strong inducer of several drug-metabolizing enzymes, including CYP3A. Hence, rifampin-induced CYP3A activity may decrease the effect of oxycodone.

References

• Ref 1: Oxycodone Resistance Due to Rifampin Use in an Osteosarcoma Patient with Tuberculosis .Am J Case Rep. 2017 Oct 24;18:1130-1134. doi: 10.12659/ajcr.905637. 10.12659/ajcr.905637